Agfa-Gevaert NV (EBR:AGFB)
Belgium
· Delayed Price · Currency is EUR | Market Cap | 73.69M |
| Revenue (ttm) | 1.09B |
| Net Income (ttm) | -71.00M |
| Shares Out | 154.82M |
| EPS (ttm) | -0.46 |
| PE Ratio | n/a |
| Forward PE | 14.54 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,152 |
| Average Volume | 69,684 |
| Open | 0.476 |
| Previous Close | 0.476 |
| Day's Range | 0.472 - 0.480 |
| 52-Week Range | 0.419 - 1.180 |
| Beta | 0.53 |
| RSI | 46.61 |
| Earnings Date | Apr 10, 2026 |
About Agfa-Gevaert NV
Agfa-Gevaert NV develops, manufactures, and markets various analog and digital systems worldwide. It operates through four segments: HealthCare IT, Digital Print and Chemicals, Radiology Solutions, and Contractor Operations and Services (CONOPS). The Healthcare IT segment provides healthcare’s enterprise imaging platform. The Digital Print & Chemicals segment offers printers, inks, and software for sign and display and packaging printing companies; inkjet inks and fluids for various industrial inkjet applications, such as signs, displays, billb... [Read more]
Financial Performance
In 2025, Agfa-Gevaert NV's revenue was 1.09 billion, a decrease of -4.57% compared to the previous year's 1.14 billion. Losses were -71.00 million, -22.83% less than in 2024.
Financial StatementsNews
Agfa-Gevaert: Convening of Annual General Meeting
April 10, 2026 Regulated information Agfa-Gevaert: Convening of Annual General Meeting Mortsel, Belgium – April 10, 2026 Unofficial translation from the Dutch version AGFA-GEVAERT NAAMLOZE VENNOOTSCHA...
Agfa-Gevaert NV Earnings Call Transcript: Q4 2025
Q4 delivered record EBITDA and strong cash flow, offsetting a challenging year marked by Radiology decline and currency headwinds. HealthCare IT cloud transition accelerated, DPS faced setbacks, and restructuring costs will pressure 2026 cash flow, but profitability is expected to improve.
Agfa-Gevaert Group in 2025: strong Q4 profitability and free cash flow – good step-up in FY profitability in HealthCare IT and Digital Print & Chemicals
Regulated information March 11, 2026 - 7:45 a.m. CET Agfa-Gevaert Group in 2025: strong Q4 profitability and free cash flow – good step-up in FY profitability in HealthCare IT and Digital Pri...
Agfa-Gevaert NV Earnings Call Transcript: Q3 2025
Q3 saw a sharp decline in medical film and a rapid shift to cloud in HealthCare IT, impacting short-term results but driving strong order intake. Cost-cutting and restructuring are being accelerated, with positive cash flow and improved net results year-over-year.
Agfa-Gevaert NV Earnings Call Transcript: Q2 2025
H1 2025 saw strong HealthCare IT growth and improved cash flow, but rapid decline in the medical film market and subdued digital printing and green hydrogen segments weighed on EBITDA. A EUR38 million Agfa Photo gain boosted net results, and further restructuring is underway.
Agfa-Gevaert NV signs new revolving credit facility - Regulated information - Contains inside information
August 1, 2025 – 6.00 PM CET Regulated information - Contains inside information Agfa-Gevaert NV signs new revolving credit facility Mortsel, Belgium – August 1, 2025 – 6.00 p.m. CET Agfa-Gevaert NV h...
Arbitral Tribunal acting under ICC Rules of Arbitration issues final award in an arbitration between Agfa-Gevaert and the insolvency receiver of AgfaPhoto GmbH
June 27, 2025 - 1.45 PM CET Regulated information – Contains inside information Arbitral Tribunal acting under ICC Rules of Arbitration issues final award in an arbitration between Agfa-Gevaert and th...
Agfa-Gevaert NV Earnings Call Transcript: Q1 2025
Q1 2025 saw stable results with strong growth in healthcare IT offsetting declines in film and radiology, especially in China. The outlook for healthcare IT is upgraded, while DPC and ZIRFON face subdued growth due to market delays. Cost-saving measures and innovation support future performance.
The Agfa-Gevaert Group in Q1 2025: adjusted EBITDA stable versus Q1 2024 – improved mix and good cost control compensated for film market decline
Regulated information May 14, 2025 - 7:45 a.m. CET The Agfa-Gevaert Group in Q1 2025: adjusted EBITDA stable versus Q1 2024 – improved mix and good cost control compensated for film market de...
Annual General Meeting of Agfa-Gevaert NV - regulated information
May 13, 2025 – 5.40 PM CET Regulated information Annual General Meeting of Agfa-Gevaert NV Mortsel, Belgium – May 13, 2025 – 5.40 p.m. CET At Agfa-Gevaert's Annual General Meeting, the 2024 financial ...
Agfa-Gevaert NV Earnings Call Transcript: Q4 2024
Record 2024 results driven by HealthCare IT, DPS, and ZIRFON, offsetting film decline. Transformation program underway, strong order intake, and growth engines expected to continue momentum in 2025, with cautious guidance due to subscription model transition.
The Agfa-Gevaert Group in 2024: strong performance from growth engines offsets decline in traditional film markets - regulated information
Regulated information March 12, 2025 - 7:45 a.m. CET The Agfa-Gevaert Group in 2024: strong performance from growth engines offsets decline in traditional film markets The Agfa-Gevaert Group ...
Extraordinary General Meeting of Agfa-Gevaert NV - regulated information
March 11, 2025 – 5.40 PM CET Regulated information Extraordinary General Meeting of Agfa-Gevaert NV Mortsel, Belgium – March 11, 2025 – 5.40 p.m. CET On Tuesday, March 11, Agfa held an Extraordinary G...
Special General Meeting of Agfa-Gevaert NV
February 28, 2025 – 5.40 PM CET Regulated information Special General Meeting of Agfa-Gevaert NV Mortsel, Belgium – February 28, 2025 – 5.40 p.m. CET On Friday, February 28, Agfa held a Special Genera...
Agfa-Gevaert NV Earnings Call Transcript: Q3 2024
DPC delivered strong double-digit growth, becoming the main profit driver, while Healthcare IT's rapid cloud transition boosted order intake but delayed revenue recognition. Radiology faced accelerated film market decline, prompting a major restructuring program.
The Agfa-Gevaert Group in Q3 2024: stable sales, adjusted EBITDA at 15 million euro - regulated information
Regulated information November 14, 2024 - 7:45 a.m. CET The Agfa-Gevaert Group in Q3 2024: stable sales, adjusted EBITDA at 15 million euro
Fiona Lam appointed as CFO for the Agfa-Gevaert Group - Regulated information - Contains inside information
October 14, 2024 - 7:45 a.m. CET Regulated information - Contains inside information Fiona Lam appointed as CFO for the Agfa-Gevaert Group Mortsel, Belgium – October 14, 2024 – 7:45 a.m.
Agfa-Gevaert NV Earnings Call Transcript: H1 2024
Q2 saw strong order intake in Healthcare IT, robust DPC and ZIRFON growth, and a positive net profit, offset by continued radiology weakness. A €50 million productivity program was launched, and working capital is expected to normalize by year-end.
The Agfa-Gevaert Group in Q2 2024: solid quarter, powered by growth engines - regulated information - inside information
Regulated information – Inside information August 28, 2024 - 7:45 a.m. CET The Agfa-Gevaert Group in Q2 2024: solid quarter, powered by growth engines
Agfa-Gevaert NV Earnings Call Transcript: Q1 2024
The Agfa-Gevaert Group in Q1 2024: weak start of the year, full year outlook maintained - regulated information
Regulated information – May 14, 2024 - 7:45 a.m. CET The Agfa-Gevaert Group in Q1 2024: weak start of the year, full year outlook maintained HealthCare IT: Soft quarter following a strong Q4 ...
Agfa-Gevaert NV Earnings Call Transcript: H2 2023
Correction: The Agfa-Gevaert Group in 2023: Group EBITDA increases by 52%, powered by its growth engines - regulated information
CORRECTION ONLY IN DUTCH VERSION Regulated information – March 13, 2024 - 7:45 a.m. CET The Agfa-Gevaert Group in 2023: Group EBITDA increases by 52%, po...
The Agfa-Gevaert Group in 2023: Group EBITDA increases by 52%, powered by its growth engines - regulated information
Regulated information – March 13, 2024 - 7:45 a.m. CET The Agfa-Gevaert Group in 2023: Group EBITDA increases by 52%, powered by its growth engines HealthCare IT: Strong improvement in profit...